Summary: Regulatory T cells (T reg ) are important regulators of immune responses. In acute myeloid leukemia (AML) patients before/after immunotherapy (stem cell transplantation or donor lymphocyte infusion), their suppressive role can contribute to suppress severe graft-versus-host reactions, but also to impair antileukemic reactions. As leukemia-derived dendritic cells (DC leu ) are known to improve the antileukemic functionality of T cells, we evaluated the composition and development of distinct T reg subtypes in AML patients (n = 12) compared with healthy probands (n = 5) under unstimulated conditions and during stimulation with DC leu -containing DC (DC) or blast-containing mononuclear cells (MNC) in 0-to 7-day mixed lymphocyte cultures by flow cytometry. T-cell subgroups in AML patients were correlated with antileukemic functionality before and after DC or MNC stimulation by functional fluorolysis assays. (1) AML patients' T cells presented with significantly higher frequencies of T reg subgroups in unstimulated T cells compared with healthy probands. (2) After 7 days of DC or MNC stimulation, all T reg subtypes generally increased; significantly higher frequencies of T reg subtypes were still found in AML patients. (3) Antileukemic cytotoxicity was achieved in 36% of T cells after MNC compared with 64% after DC stimulation. Antileukemic activity after DC but not after MNC stimulation correlated with significantly lower frequencies of T reg subtypes (CD8 + T reg /T eff/em reg ). Furthermore, cut-off values for T reg subpopulations could be defined, allowing a prediction of antileukemic response. We demonstrate a crucial role of special T reg subtypes in the mediation of antileukemic functionality. High CD8 + T reg , T eff/em reg , and CD39 + T cells correlated clearly with a reduced antileukemic activity of T cells. DC stimulation of T cells contributes to overcome impaired antileukemic T-cell reactivity. Refined analyses in the context of clinical responses to immunotherapies and graft versus host reactions are required.
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Until now, several soluble or cellular factors are known that regulate immune mechanisms in healthy individuals. However, in tumor patients, unbalanced regulatory mechanisms can contribute to immune escape mechanisms through which leukemic blasts can escape the killing by the immune system 3 : downregulation of HLA class I expression on tumor cells 4 or a defective antigen processing and expression on tumor cells protect them from elimination by cytotoxic T lymphocytes (CTL). 5 Another escape mechanism uses the disruption of the Fas/FasL system, which induces apoptosis. Furthermore, soluble factors such as the immunosuppressive cytokines interleukin (IL)-10 or tumor growth factor-b, or FasL and 4-1BBL released by T cells, dendritic cells (DC), or tumor cells can limit the immune surveillance because of insufficient lymphocyte stimulation in an inhibitory microenvironment. 6, 7 Moreover, we and others have already shown that regulatory soluble factors produced by host T cells or DC contribute to the regulation and mediation of antileukemic T-cell function. 3 Moreover, cellular factors such as regulatory T cells (T reg ) consisting of naturally occurring T reg and several subgroups of extrathymically activation-induced T reg are known to regulate immune responses. T reg are classically divided into naturally occurring CD4 + CD25 + FOXP3 + T reg ( n T reg ) and activation-induced T reg ( i T reg ) appearing after peripheral antigen stimulation. 8 i T reg can belong to CD4 + and CD8 + T cells, whereas n T reg belong only to CD4 + T cells, and form about 1%-2% of the peripheral blood cells. 9 From a clinical point of view, T reg is a 2-edged sword. On the one hand, T reg physiologically maintain the peripheral immune tolerance and are able to prevent excessive immune responses in allergy or autoaggressive immune reactions in autoimmune diseases, transplantations, or graft-versus-host disease. [10] [11] [12] [13] In humans suffering from the IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome, a mutation in the FOXP3 gene leads to a deficiency of T reg function with severe clinical autoimmune inflammatory disease. 14, 15 On the other hand, increased amounts of T reg can diminish effective antitumor T-cell responses in patients with cancer. [16] [17] [18] In the past years, several attempts have been made to identify specific T reg markers and to determine the mechanisms of T reg function. Originally, regulatory T cells were defined as "CD8 + suppressor T cells" and later on as CD25 + CD4 + T cells. 19 A more specific marker was found with the identification of the transcription factor FOXP3 and its key role in the development and function of T reg . 20, 21 In addition, surface markers such as CTLA-4 (CD152 + ), LAG-3, CD39 + CD73 + , and a low expression of the IL-7 receptor (CD127 low ) have contributed to a refined definition of T reg . A common disadvantage of all of these markers is their potentially "unspecific" upregulation during the activation of CD4 + T cells. 22 Regarding the function of T reg , 4 basic mechanisms are postulated for their suppressive function including their production of inhibitory cytokines such as tumor growth factor-and IL-10, 23, 24 their potential of a granzyme Bdependent cytolysis, 25 their potential to downregulate IL-2-mediated metabolism and immunosuppressive adenosines generated through the hydrolysis of ATP by the ectoenzymes CD39 + and CD73 +, 26, 27 and their suppression of DC-mediated T-cell stimulation through the upregulation of CD152 + . 28 Recent findings of our group showed that an inhibitory microenvironment as established by blasts can impair an antileukemic T-cell response, but can be overcome by the conversion of leukemic blasts to leukemia-derived DC (DC leu ). 29 Furthermore, we could work out relevant soluble factors (eg, released cytokines) or cells (eg, amounts of DC leu and mature DC) that are important and predictive key players in the successful mediation of antileukemic, cytotoxic T cells or the clinical response to immunotherapy. However, there are still cases where no antileukemic function of T cells after DC stimulation could be achieved. 30, 31 Thus, the aims of this study were as follows: (1) to evaluate compositions of several T reg subgroups (eg, CD4 + T reg , CD8 + T reg , T naive reg ) in uncultured peripheral bloodmononuclear cells from healthy probands and AML patients; (2) to investigate the development and recruitment of T reg subgroups during the stimulation of T cells with DC leu -containing DC ('DC') or blast-containing mononuclear cells ('MNC') in AML patients compared with healthy probands; (3) to correlate T-cell expression profiles with the antileukemic function of 'DC'-stimulated or 'MNC'-stimulated T cells in AML patients; and (4) to evaluate potential antileukemically predictive values of T reg subgroups.
MATERIALS AND METHODS

Sample Collection
After obtaining informed consent, heparinized blood samples were taken from patients. MNCs were isolated from whole blood samples by density gradient centrifugation (Ficoll-Hypaque; Biochrom, Berlin, Germany), and then washed and suspended in phosphate-buffered saline without Ca 2 + and Mg 2 + (Biochrom). Cell counts were quantified by Neubauer counting chambers, frozen with standardized procedures, and stored in liquid nitrogen until use.
Patients' Characteristics and Diagnostics
Diagnosis of AML and MDS cases was based on the French-American-British (FAB) classification. Samples from 12 patients with AML in acute stages of the disease were used as sources for DC generation. Sources for T cells were healthy stem cell donors ("donors," n = 1), patients before SCT, all of them in active stages of the disease ("autologous," n = 6), or patients after SCT ("after SCT", n = 5), with 3 of them in remission and 2 of them at relapse after SCT (Table 1) . Patients' age at diagnosis was on average 48 years (range, 5-70 y), and the female to male ratio was 1:1. Three patients presented with undifferentiated leukemia (M0 n = 2, M1 n = 2) and 1 with immature granulocytic leukemia (M2 n = 1). Monocytic leukemia was diagnosed in 6 patients (M4 n = 4, M5 n = 1). The 1 MDS case was a chronic myelomonocytic 
DC Generation
DC leu -containing DC were generated from AML patients' MNC obtained in active stages of the disease (first diagnosis, persisting disease, relapse before or after SCT) and afterward used for mixed lymphocyte cultures (MLC) using stem cell donors' or patients' autologous T cells or T cells after SCT (Table 1) .
Thawn MNCs were pipetted in 12-well tissue culture plates in 1 mL Xvivo 15 (Bio Whittaker Europe, Verviers, Belgium) FCS-free medium. DCs were generated from blood samples according to a refined strategy culturing cells in a minimalized assay with 3 DC-generating methods (MCM-Mimic, Picibanil, Ca-Ionophore, Table 2 ) in parallel, as described by us. [31] [32] [33] All of the substances used for DC generation are approved for human treatment.
For the analysis of a successful generation of DC, cells were quantified by flow cytometry using patient-specific "blast"-staining antibodies (CD33, CD13, CD15, CD65, CD34, and CD117) according to diagnostic reports in combination with DC-staining antibodies (CD1a, CD1b, CD40, CD80, CD83, CD86, and CD206) as described. 34 We defined DC generation as successful if at least >10% DC and >5% leukemia-derived DC (DC leu ) could be generated in the MNC fraction. 32 DC leu were defined by the coexpression of blast-with DC-markers. The method resulting in the highest DC count was chosen for quantitative generation of DC.
We generated DC successfully in every given case of our 12 patient and 5 healthy proband samples according to procedures already described by members of our group. 30, 32 AML samples presented with on average 20% ± 14% DC (range, 10%-51%) and 6% ± 2% DC leu (range, 5%-10%) after cultivation in selected best DC medium for individual patients. We selected Picibanil, 3 times Ca-Ionophore, and 7 times MCM-mimic.
MLC
As shown in Table 1 CD3 + T cells (later on used as "effector" T cells) were positively selected (Milteney Biotech, Bergisch-Gladbach, Germany, 1 Â10 6 cells/well) from MNC from patients (autologous n = 6), from matched stem cell donors (n = 1), or from patients in remission or at relapse after stem cell transplantation (n = 5, Table 1 , right side) and cocultured with "stimulator-cells": irradiated (20 Gy) AML blast-containing MNC [2.5Â 10 4 MNC (T'MNC')] and in parallel with irradiated DC leu -containing AML DC [2.5Â 10 4 DC (T'DC')] in 1 mL RPMI-1640 medium (Biochrom, Berlin, Germany) containing 15% human serum (PAA) and IL-2 50 U/mL (Proleukin R5, Chiron, Munich, Germany). T-cell stimulation was performed using a cell suspension containing a mixture of blasts-converted DC (DC leu ), blasts, DC, monocytes, and lymphocytes ('DC'). Total DC counts in the MLC were adjusted to 2.5Â 10 4 DC and T-cell counts adjusted to 1 Â10 6 /well. After 2-fold restimulation with 2.5 Â10 4 'DC' or 'MNC', supplementation of IL-2 (50 U/mL), and half medium exchange on days 3 and 5, cells were harvested on days 7-8 and the cytotoxicity fluorolysis assay was carried out. DC (generated from 5 healthy monocytes containing MNC) or MNC served as healthy "stimulator cells" for autologous "effector" T cells prepared from these healthy donors, as described. 30, 32 Cell Characterization by Flow Cytometry Flow cytometric analysis was carried out using monoclonal mouse antihuman antibodies (moAbs) labeled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), tandem Cy7-PE conjugation (PC7), or allophycocyanin (APC , and CD71 b were used as APCconjugated moAbs.
For analysis and quantification of lymphocytes, monocytes, and leukemic blasts before culture, the total MNC fraction was gated. Proportions of positive events in defined gates compared with the isotype controls were calculated using the Cell Quest software. Quantification and characterization of DC and DC leu were performed by flow cytometry according to our gating strategy already described by former groups. [30] [31] [32] [33] [34] To quantify and characterize the several T-cell subpopulations, we defined a "lympho-gate" surrounding lymphocytes and monocytes. T-cell subgroups were defined by antigen coexpression before and after 'MNC' or 'DC' stimulation as shown in Table 3 . Flow cytometric analyses were carried out on days 0, 1, 3, 5, and 7 followed by a functional cytotoxic fluorolysis assay on days 7 or 8 as described below.
Cytotoxicity Fluorolysis Assay
The lytic activity of effector T cells was measured by a fluorolysis assay by counting viable blast target cells, labeled with specific fluorochrome antibodies, before and after effector cell contact as described. 30 'DC'-stimulated or 'MNC'-stimulated T cells from healthy matched donors (n = 1), from AML patients (autologous n = 5), or from AML patients after SCT (after SCT n = 5) and unstimulated T cells were cocultured with thawn blasts as target cells for 4 or 24 hours, as described. Before culture, blasttarget cells were stained for 15 minutes with 2 FITC and/or PE-conjugated blast-specific antibodies and subsequently cocultured with effector cells. As a control, target and effector cells were cultured separately and mingled with T cells shortly before FACS analysis. To evaluate the amount of viable (7AAD À ) target cells and to quantify the cell loss after 24 hours of incubation, cells were harvested, washed in phosphate-buffered saline, and resuspended in a FACS flow solution containing 7AAD (BD, Biosciences Pharmingen) and a defined number of fluorospheres beads (Becton Dickinson, BD, Heidelberg, Germany). Viable cells were gated in an SSC/7AAD À gate, and viable cells coexpressing the patient-specific blast phenotype were quantified later by taking into account defined counts of calibration beads as described. Cells were analyzed in a FACS Calibur Flow Cytometer using the CELL Quest software (Becton Dickinson). The percentage of lysis was defined as the difference between proportions of viable blasts before and after effector cell contact. Results are given in Table 1 .
Statistical Methods
Means, SDs, and results with the 2-tailed t test were evaluated with a personal computer using Excel2007 (Microsoft). Differences were considered as significant if the P-value was <0.05.
RESULTS
We wanted to enlighten the development, activation, proliferation, and differentiation of T cells before and especially after 'MNC' or 'DC' stimulation in AML patients and healthy probands with special focus on the role of regulatory T cells and T reg subtypes (as given in Table 3 ) in the mediation of antileukemic activities of 'MNC'-stimulated, 'DC'-stimulated, or unstimulated T cells.
'DC' Stimulation Leads to Alteration in T-cell Profiles
We and others have already demonstrated the variable blast-lytical outcome of T cells after 'MNC' or 'DC' stimulation. 30 We compared the expression of several T-cell markers (as listed in Table 2 ) on unstimulated T cells (day 0) and after stimulation (day 7) in MLC. To prevent any unwanted 'MNC' or 'DC' stimulation of T cells, measurements on day 0 were carried out "on ice." We studied the expression of activation and proliferation markers on uncultured T cells from AML patients and from healthy probands. Low amounts of proliferating or activated T cells (CD3 + T cells expressing CD69, CD71, and CD122 or CD4 + /CD8 + T cells expressing CD25) were found on unstimulated T cells (d0) in the MLC of healthy donors and AML patients (Fig. 1A) . However, healthy probands showed significantly higher levels of CD127 + CD4
+ (93% ± 7% vs. 65% ± 21%) and CD127 + CD8
+ (86% ± 10% vs. 52% ± 17%) T cells compared with AML patients (P < 0.005, Fig. 1A) .
In summary, this means that low amounts of proliferating T cells were found in unstimulated T cells from healthy donors or AML patients, but significantly higher proportions of CD4 + /CD8 + T cells expressed CD127 in healthy compared with AML donors.
AML Patients Present With Significantly Higher Levels of Several T reg Subgroups Before 'DC' or 'MNC' Stimulation
We compared the expression of common regulatory cell markers on uncultured T cells of AML patients and healthy probands.
Comparable amounts of unstimulated (d0) CD3 + T cells expressing CD152 or CD4 + T cells expressing CD39 (with or without CD25/CD127 expression) were found in healthy probands or AML patients (Fig. 1B, upper part) . However, healthy probands showed significantly lower amounts of CD4 + T reg in CD4 + T cells (11% ± 5% vs. 29% ± 11%, P < 0.005) or CD8 + T reg in CD8 + T cells (4% ± 2% vs. 14% ± 9%, P < 0.005) or CD39 + cells in MLC fractions (10% ± 6% vs. 25% ± 6%, P < 0.005) compared with AML patients. In contrast, we found significantly higher amounts of CD73 + cells in MLC in healthy probands compared with AML patients (33% ±5% vs. 19% ± 11%, P < 0.005, Fig. 1B, upper part) .
Furthermore we found significantly lower amounts of all T reg subsets in unstimulated cell fractions in healthy probands compared with AML patients: T naive reg in MLC (1% ± 1% vs. 4% ± 4%, P < 0.05), T naive reg in T naive , (12% ± 17% vs. 28% ± 17%, P < 0.05), T eff/em reg in MLC (5% ± 3% vs. 10% ± 7%, P < 0.05), T eff/em reg in T eff/em (9% ± 7% vs. 19% ± 9%, P < 0.005), T cm reg in MLC (1% ± 1% vs. 4% ± 2% P < 0.005), and T cm reg in T cm (17% ± 14% vs. 31% ± 13%, P < 0.05) (Fig. 1B, lower part) .
In summary, we found significantly lower frequencies of several T reg subgroups in unstimulated T cells in healthy probands compared with AML patients.
Profiles of 'MNC'-stimulated Versus 'DC'-stimulated T Cells After We compared the expression of common regulatory cell markers on T cells from AML patients and healthy probands after stimulation with 'MNC' or 'DC', respectively ( Fig. 2A) Fig. 2A) . However, compared with AML patients, healthy probands showed significantly higher levels of CD127 + CD4
+ (78% ± 20% vs. 26% ± 19%, P < 0.05) and CD127 + CD8
+ T cells on day 7 (62% ± 27% vs. 17% ± 14%, P < 0.05, Fig. 2A ). After 7 days of 'MNC' stimulation, similar expression patterns could be observed (data not shown).
AML Patients Present With Significantly
Higher Levels of T cm reg and T eff/em reg After 'DC' or 'MNC' Stimulation Compared With Healthy Probands
We compared the expression of various regulatory cell markers on T cells from AML patients and healthy probands after stimulation with 'MNC' or 'DC', respectively (Fig. 2B) .
Concerning the expression of CD73 
CD127
low T cells, no significant differences between AML patients and healthy probands could be observed after 7 days with 'DC' stimulation (Fig. 2B) . Tendentially, healthy probands showed lower amounts of CD4 + T reg (referred to CD4 + cells) and CD8 + T reg (referred to CD8 + cells) compared with AML patients (P < 0.1) (Fig. 2B, upper part) . However, compared with AML samples, healthy probands presented with significantly lower amounts of T cm reg (26% ± 8% vs. 58% ± 21%, P < 0.005) and T eff/em reg (33% ± 14% vs. 59% ± 16%, P < 0.05) and tendentially lower amounts of T naive reg (53% ± 31% vs. 78% ± 22%, Pr0.1, Fig. 2B , lower part) after 7 days of 'DC' stimulation. Values after 7 days of 'MNC' stimulation in AML patients and healthy probands were comparable to values after 'DC' stimulation (data not shown).
In summary, we still found significantly higher levels of T reg subtypes in AML patients compared with healthy probands on day 7.
Kinetic Profiles of Surface Markers on T Cells in the Time Course of 'DC' or 'MNC' Stimulation (Day 0-7)
We examined the kinetic development of surface marker profiles, performed measurements on days 0, 1, 3, 5, and 7, and compared statistical profiles of day 0 and 7 ( Fig. 3) .
Expression Profiles of Activation and Proliferation Are Comparable in AML Patients and Healthy Probands
Proportions of CD25 + T cells stayed rather constant during 'DC' stimulation between day 0 and day 7 in both groups (Fig. 3A) . In general (with the exception of CD127), T cells from healthy probands showed a similar kinetic development during 'DC' stimulation compared with AML patients. As shown in Fig. 3A , the kinetics of healthy probands showed no significant decrease in CD127 + T cells, whereas the expression on CD4 + T cells decreased significantly from 63% ± 23% to 26% ± 19% in AML patients (P < 0.005) between day 0 and 7. We could demonstrate a significant increase in CD69 + T cells in AML patients (2%±2% to 18% ± 20%, P < 0.05) and healthy probands (6% ± 7% to 21% ± 9%, P < 0.05) between day 0 and 7 of 'DC' stimulation (P < 0.05, Fig. 3A) . CD71 + T cells of AML patients (8% ± 9% to 28% ± 19%, P < 0.05) and healthy probands (15% ± 15% to 39% ± 22%, P < 0.1) and CD122 + T cells of AML patients (4% ± 2% to 12% ± 9%, P < 0.05) and healthy probands (4% ± 2% to 12% ± 8%, P < 0.1) showed a significant continuous increase, reaching high values on days 3-5.
During stimulation with 'MNC', we could demonstrate an analogous kinetic development as with 'DC' stimulations in healthy and AML samples (data not shown).
In summary, we could show that after 7 days of stimulation with 'DC' or 'MNC', all 17 MLC presented with an increase in immunologic activation markers. Compared with day 0, AML patients and healthy probands showed a significant upregulation of CD69 + , CD71
+ , and CD122
+ T cells and a significant downregulation of CD127 + T cells (only in AML) after 'DC' stimulation and after 'MNC' stimulation (data not shown).
AML Patients and Healthy Probands Show a Continuous Increase in T reg Subgroups
Similarly, no significant changes in the proportion of CD152 + T cells between d0 and d7 were seen in AML patients and healthy probands (Fig. 3B) . A significant increase in the proportion of T-cell subtypes between d0 and d7 was found in AML patients and in healthy probands for T naive reg (AML: 32% ± 20% to 78% ± 22%, P < 0.005; healthy: 13% ± 22% to 53% ± 31%, P < 0.05), T cm (AML: 35% ± 14% to 58% ± 21%, P < 0.05; healthy: 18% ± 17% to 26% ± 8%, P < 0.1), T eff/em reg (AML: 20% ± 10% to 59% ± 16%, P < 0.005; healthy: 11% ± 8% to 33% ± 14%, P < 0.05), CD8 + T reg (AML: 15% ± 9% to 53% ± 22%, P < 0.005; healthy: 4% ± 2% to 33% ± 19%, P < 0.05), and CD4 + T reg (AML: 31% ± 11% to 50% ± 16%, P < 0.005; healthy: 12% ± 6% to 35% ± 15%, P < 0.05). Regarding the ectoenzymes CD39
+ and CD73 + , we could detect a continuous and tendentially significant decrease in CD73 + cells in AML patients and a significant decrease in healthy probands (AML: 19% ± 11% to 13% ± 08%, P < 0.1; healthy: 33% ± 5% to 20% ± 8%, P < 0.05). CD39 However, as shown in Fig. 3B , in healthy probands, we found After 'MNC' stimulation, we could demonstrate an analogous kinetic development (data not shown).
In summary, all subtypes of T reg increased significantly after 'DC' or 'MNC' stimulation among AML patients and healthy probands. In AML patients, CD39
+ T reg showed no increase after 7 days of 'DC' or 'MNC' stimulation, whereas a tendentially significant increase in CD39
+ T reg and a significant increase in CD39 + cells was observed after 'DC' stimulation in healthy probands. We could not detect any significant differences in the pattern of regulatory T cells after 'DC' or 'MNC' stimulation in AML patients and in healthy probands.
Correlation of T-cell Expression Profiles With the Antileukemic Function of 'MNC'-stimulated, 'DC'-stimulated, or Unstimulated T Cells in AML Cases
We have already demonstrated that stimulation with DC leu improves the antileukemic function of T cells. Thus, we wanted to examine the potential differences of surface marker expression concerning the activation and regulation of T cells in the context of the antileukemic function of 'DC'-stimulated/'MNC'-stimulated T cells. We subdivided our cases into those that gained lytic activity ("lysis") and those that were not able to lyse blasts ("nonlysis") after 'DC' or 'MNC' stimulation and compared the surface marker profiles regarding the expression of activation, proliferation, and regulation markers on "MNC-stimulated," "DC-stimulated," or unstimulated T cells. Functional assays showed that 'MNC' stimulation induced antileukemic cytotoxicity in 4 of 11 cases (36%) compared with 7 of 11 cases (64%) after 'DC' stimulation. Unstimulated T cells showed lytic activity in 5 of 10 cases (50%). Unstimulated T cells showed an average lytic efficiency of 60% of blasts (range, 30%-93%), 'MNC'-stimulated T cells of 41% (range, 9%-80%), and 'DC'-stimulated T cells of 62% (range, 12%-85%) of blasts. Cases with lysis after 'DC' stimulation consisted of T cells after SCT (n = 4) and autologous T cells (n = 3). Cases with lysis after 'MNC' stimulation were T cells from patients after SCT (n = 3) and in autologous T cells in 1 case. T-cell sources of cases with lysis of unstimulated T cells were T cells after SCT (n = 4) and in 1 case autologous T cells. Results of antileukemic activity in individual cases are given in Table 1 (right side).
T-cell Profiles of T Cells Before Stimulation With 'DC' or 'MNC' in AML Cases
Expression Profiles of Activation and Proliferation Markers on T Cells Before 'DC' or 'MNC' Stimulation in Lysis and Nonlysis Groups of AML Cases Do Not Differ
On day 0 before 'DC' stimulation, we found no significant differences between the lytically active and nonactive groups regarding the expression profiles of activation and proliferation markers (Fig. 4A, left side) .
Tendentially Lower Proportions of CD8
+ T reg in the Lysis Group Before 'DC' But Not Before 'MNC' Stimulation On day 0 before 'DC' stimulation, we found no significant differences between the lytically active and nonactive groups regarding the expression profiles of CD152 (Fig. 4B, left side) . However, we found tendentially lower proportions of CD8 + T reg (referred to CD8 + cells) before 'DC' stimulation in the later-on lysis group compared with the nonlysis group (10% ± 3% vs. 23% ± 12% Pr0.1; Fig. 4B, left side) .
Before 'MNC' stimulation, we could not detect any significant differences in the levels of any regulatory subgroups between the later on lysis and nonlysis groups (data not shown). , and CD127 + ) were found between the lytically active and nonactive groups after 'DC' stimulation (Fig.4A, right side) .
T-cell Profiles
The Lysis Group Presents With Significantly Lower Amounts of CD8
+ T reg and T eff/em reg After 'DC' But Not After 'MNC' Stimulation in AML Cases No significant differences in proportions of regulatory T-cell subtypes were found in proportions of the following markers in the lytically active compared with the nonactive group after DC stimulation (Fig. 4A, right + cells) were found in cases with lysis than in cases without lysis after DC stimulation (29% ± 14% compared with 44% ± 13%, Pr0.1). Significantly lower proportions of CD8 + T reg (referred to as CD8 + cells, 45% ± 15% compared with 76% ± 13%, P < 0.05) and T eff/em reg (referred to as T eff/em ; 49% ± 12% compared with 75% ± 7%, P < 0.005) were found in the lysis compared with the nonlysis group after 'DC' stimulation (Fig. 4B, right side) . It is interesting to note that these correlations between expression profiles concerning regulatory T cells and antileukemic functionality were not detectable after 'MNC' stimulation.
In summary, we found that low proportions of T reg subpopulations (CD8 + T reg , T eff/em reg , and CD39 + CD4 + ) in unstimulated and even more in 'DC'-stimulated cell fractions went along with good antileukemic ex vivo activity (Fig. 4B) .
Cut-off Values of T reg Subpopulations Contribute to Predict the Antileukemic Reactivity of Unstimulated and Even More of 'DC'-stimulated T Cells in AML Cases
To gain a better prediction of the antileukemic behavior of 'DC'-stimulated or unstimulated T cells, we subgrouped our cases according to their antileukemic function and evaluated predictive cut-off values. These values could be defined for the following regulatory subgroups (before or after 'DC' stimulation): CD8 + T reg (referred to as CD8 + cells), T eff/em reg (referred to as T eff/em ), T cm reg (referred to as T cm ), and T naive reg (referred to as T naive , Fig. 5 ). In detail, we could show that cases with <60% of CD8 + T reg in all CD8 + cells, those with <60% of T eff/em reg in all T eff/em cells, and those with <70% of T cm reg in all T cm cells showed an 80%-100% antileukemic T-cell activity. Cases with higher proportions of these regulatory T cells had a high probability to belong to the nonlytic group (range, 67%-100%). These cut-off values became more distinctive after 'DC' stimulation compared with unstimulated samples and could not be defined after 'MNC' stimulation. Moreover, we could not define any cut-off values regarding the proportions of the activation or the proliferation markers expressed.
Furthermore, we tried to compare these cellular findings with the patients' clinical outcomes. Five of our 12 patients received immunotherapy, of whom 3 patients did not respond, 1 responded, and 1 died of SCT-related complications. The patient responding to immunotherapy had lower proportions of CD8 + T reg and T eff/em reg before stimulation and higher proportions of T naive reg before and after DC stimulation compared with the nonresponders (data not shown).
In summary, our findings show that cases with an antileukemic function presented in general with lower amounts of T reg subgroups (CD8 + T reg and T eff/em reg ) in unstimulated and even more in 'DC'-stimulated cases.
DISCUSSION
Regulatory T cells (iT reg ) and their subgroups play a critical role in the mediation of immune responses. With respect to AML patients, the role of T reg is of special interest: on the one hand, the suppressive role of T reg and their ability to suppress lethal graft-versus-host disease could be demonstrated, [35] [36] [37] but on the other, high T reg counts after SCT, respectively, after adoptive T reg -cell transfer could be correlated with reduced graft-versusleukemia effects. [38] [39] [40] Recently, our research group demonstrated that the conversion of leukemic blasts into leukemia-derived DC (DC leu ), being effective professional antigen-presenting cells by inducing activation, proliferation, and differentiation of naı¨ve T cells into different effector T cells, can improve the mediation of an antileukemic T-cell response and provides a good ex vivo model to study stimulatory influences on T cells. 30 To gain new insights into the role of T reg and the mediation of antileukemic T-cell responses, we investigated the profile of unstimulated T cells, with ex vivo DC leu containing DC ('DC') or leukemic blasts containing 'MNC'-stimulated T cells in AML patients compared with healthy probands. Finally, we correlated the T reg distribution with the mediation of an effective antileukemic T-cell cytotoxicity (lysis vs. nonlysis).
First of all, the present study confirms our former findings, showing that 'DC'-stimulated T cells improve the mediation of an antileukemic T-cell response compared with 'MNC'-stimulated T cells. The present study verified that unstimulated T cells showed a reduced induction of antileukemic cytotoxicity compared with 'DC'-stimulated T cells, but a higher percentage of antileukemic function compared with 'MNC'-stimulated T cells. 30, 31 These findings contribute to the assumption that the inhibitory microenvironment induced by blasts could be abolished after blast conversion to DC leu . 29 General Activation and Proliferation After 'DC' or 'MNC' Stimulation T-cell stimulation with 'DC' or 'MNC' leads to a general T-cell activation and proliferation. 31 During 'DC' or 'MNC' stimulation, we could observe an upregulation of activation and proliferation surface markers. According to former studies, we also found the typical pattern of an early upregulation of CD69 + already on day 1 and a delayed upregulation of the proliferation marker CD71 + , reaching the maximum expression on T cells on day 5. 41, 42 The surface expression of CD25 + already had a relatively high base level on unstimulated T cells compared with other surface markers and showed no significant upregulation on activated T cells during the whole time course. Nguyen and colleagues postulated the coexpression of CD71 + and CD25 + as reliable markers for T-cell proliferation. Our data suggest the single expression of CD71 + as the most reliable marker to evaluate T-cell proliferation. As already described, we could observe a downregulation of CD127 + , the IL-7-receptor, during T-cell proliferation. 43, 44 Our observation of a significantly higher surface expression of CD127 + on unstimulated T cells in healthy probands compared with AML patients might express the higher proliferation potential of healthy T cells compared with T cells in AML patients.
CD4
+ CD25 ++ CD127 low T reg Instead of FOXP3 + T reg
Originally, T reg were defined through the expression of the intracellular transcriptional factor FOXP3 + , which is an important regulator of the development and function of T reg and is classified as one of the most reliable T reg markers. 21, 45 However, several studies described the existence of suppressive T cells not expressing FOXP3 + . 46 Several studies have demonstrated a high correlation between the expression of FOXP3 + and the low surface expression of the IL-7 receptor a chain (CD127 low ) on T reg . [47] [48] [49] It is interesting to note that Hartigan-O'Connor et al 49 found robustly suppressive CD25 + CD127 low T cells despite the low expression of FOXP3. Therefore, we decided to use CD127 low as the T reg marker in our model to address FOXP3 + and FOXP3-T reg . Moreover, by focusing on extracellular surface markers, our methodological procedures were not impaired through permeabilization techniques.
High Counts of Distinct T reg Subgroups Correlate With Cancer
It has been demonstrated that increased frequencies of T reg or a loss of T reg -mediated immune tolerance correlates with several solid cancers and hematologic diseases. 40 In the present study, we demonstrated that AML patients presented with significantly higher frequencies of several T reg subgroups in unstimulated T cells compared with healthy probands, correlating with the findings of former studies. 17, 50 Shenghui et al 51 have already shown that an elevated frequency of T reg in the peripheral blood and bone marrow is associated with a poor prognosis in AML patients. However, although most of these studies were restricted to the well-investigated CD4 Recently, several working groups have described T reg subgroups, consisting of phenotypically and functionally distinct subtypes such as naı¨ve T reg and effector T reg , because of their ability to differentiate into effector/memory cells after antigen contact. 46, [57] [58] [59] In the present study, we could demonstrate higher frequencies of CD4 + T reg and CD8 + T reg and also of T naive reg , T cm reg , and T eff/em reg in AML patients compared with healthy probands. These findings implicate that regulatory and effector T-cell subsets have a greater plasticity than originally thought.
Another T reg subgroup is defined to mediate the suppressive mechanism of adenosine produced through the ectoenzymes CD39 + (ectonucleoside triphosphate diphosphohydrolase) and CD73 + (ecto-5 0 -nucleotidase 1), which catalyze the sequential hydrolysis of ATP/ADP. 60 In humans, the expression of CD39 + is found on B cells, leukemic blasts, and T cells and T reg with restriction to T eff/em reg . 26 Szczepanski et al 17 have shown that T reg in AML patients express CD39 + and CD73
+ and consequently hydrolyze ATP more efficiently than T reg in healthy probands. In unstimulated T cells, we found a higher expression frequency of CD39 + and a lower expression frequency of CD73 + in AML patients compared with healthy probands as most of our patients were studied during chemotherapeutic treatment. These data indicate that because of tumor lysis effects, free nucleosides influence the surface expression frequencies of CD39 + and CD73 + in AML patients compared with healthy probands. Because of the different expression frequencies, we recommend the monitoring of CD39 + T reg only in AML patients without high levels of free nucleotides (due to chemotherapeutic intervention).
CTLA4 (CD152 + ) mediates suppression by binding to CD80 + and CD86 + on DC, through which these costimulatory surface molecules for T-cell activation are reduced on DC. 61 We could detect neither a significant difference in the surface expression profile of CD152 + on healthy T reg compared with the T reg of AML patients nor an increase of this surface marker during DC or MNC stimulation. These findings suggest that in this setting, CTLA-4 does not play a crucial role. Similar findings have been reported formerly. 62 
Kinetic Development of T reg Subgroups Under Stimulation
The common problem of all T reg markers is their general upregulation on activated T cells, which reduces their specific correlation to T reg . Recent publications have also shown a general in vitro expansion of CD4 + T reg by 'DC' stimulation during MLC. 63 Mahic et al 64 demonstrated an increase in CD8 + T reg by continuous antigen stimulation. During 'DC' or 'MNC' stimulation, we found a continuous increase in most of the T reg subgroups in AML patients and in healthy probands. After stimulation by MLC, we still found significantly higher levels of T cm reg and T eff/em reg and tendentially higher levels of CD4 + and CD8 + T reg in AML patients compared with healthy probands.
Previous data of our group showed an upregulation of CD39 + during ex vivo of healthy T cells with nucleosides, whereas the expression of CD73 + was downregulated (Weiler M, unpublished data). During 'DC' and 'MNC' stimulation, in the present study, we also observed an upregulation of CD39 + and a downregulation of CD73 + in healthy probands. It is interesting to note that AML patients did not show significant changes in the expression frequencies of CD39 + and CD73 + during stimulation, probably due to a high expression of CD39 + and a low expression of CD73 + antigens before culture.
The Antileukemic Functionality Correlates With Frequencies of T reg
Our data showed that an antileukemic T-cell response was achieved in 60% of AML cases after 'DC' stimulation compared with 40% after 'MNC' stimulation. Consequently, 'DC' stimulation seems to be an option to reverse T-cell anergy and to reestablish an antileukemic Tcell response, as already shown by our group. 29, 30 In the context of the present study, we could correlate differences in T reg profiles with the antileukemic functionality after 'DC', but not after 'MNC' stimulation. Moreover, ex vivo cut-off values predicting the antileukemic functionality were definable. The present study could demonstrate significantly higher proportions of CD8 + T reg and T eff/em reg in the nonlysis group compared with the lysis group after 'DC' stimulation. The expression frequencies of these T reg subgroups in the lysis group were comparable to the expression frequencies in our healthy probands. Surprisingly, we could not detect any correlations in the proportions of CD4 + T reg with the lysis or the nonlysis group.
CONCLUSIONS
In summary, our results provide new insights into the cellular profiles and the antileukemic T-cell functionality of T reg . Our findings suggest a crucial role of CD8 + T reg and T eff/em reg in the mediation of the immune escape in AML patients. Moreover, we showed that frequencies of distinctly decreased levels of T reg subtypes correlate with the reestablishment of the antileukemic functionality in a significant proportion of patients. We could even define cut-off values for T reg subtypes, which allow an estimation of the lytic potential of individual patients' T cells. CD39 + and CD73 + expression on T reg subgroups have to be discussed critically in patients with a high cellular turnover because of chemotherapy.
From a clinical point of view, our data recommend the monitoring of the distinct T reg subgroups (CD8 + T reg , and T eff/em reg ) and defining cut-off values in vivo. In the context of immunotherapeutic strategies, further experiments are necessary to learn about mechanisms involved in the suppression of antileukemic graft-versus-leukemia reactions and to create strategies to manipulate T reg subtypes (eg, by abolishing an inhibitory blast microenvironment in vivo) or to learn about mechanisms responsible for diminished graft versus host reactions and to manipulate them (eg, by elimination of autoreactive T cells).
